Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by equities researchers at UBS Group from a “buy” rating to a “neutral” rating in a research note issued to investors on Tuesday, Briefing.com reports. They currently have a $11.00 price objective on the stock, down from their previous price objective of $15.00. UBS Group’s price target points to a potential upside of 1.76% from the stock’s current price.
TEVA has been the subject of several other research reports. TheStreet raised Teva Pharmaceutical Industries from a “d+” rating to a “c-” rating in a research report on Monday, April 5th. JPMorgan Chase & Co. reissued a “hold” rating and set a $10.00 price target on shares of Teva Pharmaceutical Industries in a research report on Sunday, March 14th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $11.58.
Shares of NYSE:TEVA opened at $10.81 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.63 and a debt-to-equity ratio of 2.22. The company has a market cap of $11.81 billion, a price-to-earnings ratio of -2.94, a price-to-earnings-growth ratio of 0.87 and a beta of 1.49. Teva Pharmaceutical Industries has a 12 month low of $8.44 and a 12 month high of $13.30. The company has a 50-day moving average price of $11.02 and a 200-day moving average price of $10.61.
In related news, insider Mark Sabag sold 127,244 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 16th. The stock was sold at an average price of $11.22, for a total value of $1,427,677.68. Following the completion of the sale, the insider now owns 20,598 shares of the company’s stock, valued at $231,109.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.56% of the company’s stock.
Large investors have recently modified their holdings of the company. Ayalon Holdings Ltd. purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth $26,000. Jeppson Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $26,000. Freedman Financial Associates Inc. purchased a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $38,000. Safeguard Investment Advisory Group LLC bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth approximately $42,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at approximately $57,000. Hedge funds and other institutional investors own 51.20% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: Investing strategies using the yield curve
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.